日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium

更正:利用新型中和抗体抑制Notch4可通过靶向肿瘤内皮细胞减少小鼠癌症模型中的肿瘤生长。

Eng, Jason W-L; Kato, Yu; Adachi, Yusuke; Swaminathan, Bhairavi; Naiche, L A; Vadakath, Rahul; Sakamoto, Yoshimasa; Nakazawa, Youya; Tachino, Sho; Ito, Ken; Abe, Takanori; Minoshima, Yukinori; Hoshino-Negishi, Kana; Ogasawara, Hideaki; Kawakatsu, Tomomi; Nishimura, Miyuki; Katayama, Masahiko; Shimizu, Masashi; Tahara, Kazuhiro; Sato, Toshitaka; Suzuki, Katsuhisa; Agarwala, Kishan; Iwata, Masao; Nomoto, Kenichi; Ozawa, Yoichi; Imai, Toshio; Funahashi, Yasuhiro; Matsui, Junji; Kitajewski, Jan

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

评估乐伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者的潜在生物标志物:111/KEYNOTE-146 研究结果

Makker, Vicky; Taylor, Matthew H; Aghajanian, Carol; Cohn, Allen L; Brose, Marcia S; Simone, Christopher Di; Cao, Zhu Alexander; Suttner, Leah; Loboda, Andrey; Cristescu, Razvan; Jelinic, Petar; Orlowski, Robert; Dutta, Lea; Matsui, Junji; Dutcus, Corina E; Minoshima, Yukinori; Messing, Mark J

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

乐伐替尼联合抗PD-1抗体治疗可通过减少肿瘤相关巨噬细胞和激活干扰素通路来激活CD8+ T细胞。

Kato, Yu; Tabata, Kimiyo; Kimura, Takayuki; Yachie-Kinoshita, Ayako; Ozawa, Yoichi; Yamada, Kazuhiko; Ito, Junichi; Tachino, Sho; Hori, Yusaku; Matsuki, Masahiro; Matsuoka, Yukiko; Ghosh, Samik; Kitano, Hiroaki; Nomoto, Kenichi; Matsui, Junji; Funahashi, Yasuhiro

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model

乐伐替尼的免疫调节活性有助于其在Hepa1-6肝细胞癌模型中的抗肿瘤活性。

Kimura, Takayuki; Kato, Yu; Ozawa, Yoichi; Kodama, Kotaro; Ito, Junichi; Ichikawa, Kenji; Yamada, Kazuhiko; Hori, Yusaku; Tabata, Kimiyo; Takase, Kazuma; Matsui, Junji; Funahashi, Yasuhiro; Nomoto, Kenichi

Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models

在小鼠模型中,艾立布林的抗肿瘤作用取决于其通过血管重塑调节肿瘤微环境。

Ito, Ken; Hamamichi, Shusei; Abe, Takanori; Akagi, Tsuyoshi; Shirota, Hiroshi; Kawano, Satoshi; Asano, Makoto; Asano, Osamu; Yokoi, Akira; Matsui, Junji; Umeda, Izumi O; Fujii, Hirofumi

A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice

一种新型选择性Δ5去饱和酶抑制剂可降低饮食诱导肥胖C57BL/6J小鼠的胰岛素抵抗并减轻体重

Yashiro, Hiroaki; Takagahara, Shuichi; Tamura, Yumiko Okano; Miyahisa, Ikuo; Matsui, Junji; Suzuki, Hideo; Ikeda, Shota; Watanabe, Masanori

Integration of genomic data enables selective discovery of breast cancer drivers.

基因组数据的整合能够有选择地发现乳腺癌驱动因素

Sanchez-Garcia Félix, Villagrasa Patricia, Matsui Junji, Kotliar Dylan, Castro Verónica, Akavia Uri-David, Chen Bo-Juen, Saucedo-Cuevas Laura, Rodriguez Barrueco Ruth, Llobet-Navas David, Silva Jose M, Pe'er Dana

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.

乐伐替尼与戈伐替尼联合用药可克服肝细胞生长因子通路诱导的对血管内皮生长因子受体抑制剂的耐药性

Nakagawa Takayuki, Matsushima Tomohiro, Kawano Satoshi, Nakazawa Youya, Kato Yu, Adachi Yusuke, Abe Takanori, Semba Taro, Yokoi Akira, Matsui Junji, Tsuruoka Akihiko, Funahashi Yasuhiro